Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
CME/CE Virtual Event
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 29, 2026
12:00 PM - 01:00 PM EDT
1.00 credit
CME/CE In-Person & Virtual Event
Spotlight on B7-H3 ES-SCLC: Applying ADC Evidence in Real-World Practice
December 5, 2026
Scottsdale, Arizona
1.00 credit
Optimizing Patient Selection for Perioperative Therapy in Bladder Cancer
Optimizing Patient Selection for Perioperative Therapy in Bladder Cancer
Project Oncology®
Optimizing Patient Selection for Perioperative Therapy in Bladder Cancer
Benjamin Garmezy, MD
- Benjamin Garmezy, MD
What's Next for Urothelial Cancer Treatment?
What's Next for Urothelial Cancer Treatment?
Project Oncology®
What's Next for Urothelial Cancer Treatment?
Benjamin Garmezy, MD
- Benjamin Garmezy, MD
Key Questions Shaping Chemotherapy-Free Treatment in Mantle Cell Lymphoma
Key Questions Shaping Chemotherapy-Free Treatment in Mantle Cell Lymphoma
Project Oncology®
Key Questions Shaping Chemotherapy-Free Treatment in Mantle Cell Lymphoma
Jonathon B. Cohen, MD, MS
- Jonathon B. Cohen, MD, MS
Myeloid Mutations in ALL: Disease Risk and Prognostic Implications
Myeloid Mutations in ALL: Disease Risk and Prognostic Implications
Project Oncology®
Myeloid Mutations in ALL: Disease Risk and Prognostic Implications
Caner Saygin, MD
- Caner Saygin, MD
Reducing Cardiovascular Risk in Adult Survivors of Childhood Cancer
Reducing Cardiovascular Risk in Adult Survivors of Childhood Cancer
Heart Matters
Reducing Cardiovascular Risk in Adult Survivors of Childhood Cancer
Stephanie Dixon, MD, MPH
- Stephanie Dixon, MD, MPH
How Myeloid Mutations in ALL Inform Treatment Decisions
How Myeloid Mutations in ALL Inform Treatment Decisions
Project Oncology®
How Myeloid Mutations in ALL Inform Treatment Decisions
Caner Saygin, MD
- Caner Saygin, MD

Medical News

Medical News
Stepped Reminders Boost Lung Cancer Screening Adherence
09/17/2026
Read more
Medical News
Blood mRNA Panel May Detect Early Pancreatic Cancer
09/17/2026
Read more
Medical News
AI Tracks Colorectal Liver Metastases on Follow-up CT
09/17/2026
Read more
Medical News
Sugarbaker Mesh Lowers Parastomal Hernia After APR
09/17/2026
Read more

CME/CE

Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
CME/CE Virtual Event
Today’s CLL/SLL Decisions, Tomorrow’s Options: Practical Strategies for the Community Clinic
September 24, 2026
06:00 PM - 07:00 PM ET
1.00 credit
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
MinuteCE®
The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
MinuteCE®
Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
Virginia Kaklamani, MD, DSc
0.50 program credits
- Virginia Kaklamani, MD, DSc
0.50 program credits
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
MinuteCE®
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
Natalie S. Callander, MD
0.75 program credits
- Natalie S. Callander, MD
0.75 program credits

Clinical Practice

Moving Toward Biomarker-Driven Care in Bladder Cancer
Moving Toward Biomarker-Driven Care in Bladder Cancer
Project Oncology®
Moving Toward Biomarker-Driven Care in Bladder Cancer
Benjamin Garmezy, MD
- Benjamin Garmezy, MD
Moving Beyond Chemotherapy in Mantle Cell Lymphoma Care
Moving Beyond Chemotherapy in Mantle Cell Lymphoma Care
Project Oncology®
Moving Beyond Chemotherapy in Mantle Cell Lymphoma Care
Jonathon Cohen, MD, MS
- Jonathon Cohen, MD, MS
Supportive Care During and After CLL Treatment: What to Prioritize
Supportive Care During and After CLL Treatment: What to Prioritize
Project Oncology®
Supportive Care During and After CLL Treatment: What to Prioritize
Kerry A. Rogers, MD
- Kerry A. Rogers, MD
Adapting CV Risk Reduction Strategies for Cancer Survivorship
Adapting CV Risk Reduction Strategies for Cancer Survivorship
Heart Matters
Adapting CV Risk Reduction Strategies for Cancer Survivorship
Stephanie Dixon, MD, MPH
- Stephanie Dixon, MD, MPH

Programs

A Look at WCLC 2026: Pivotal Trials and Emerging Directions
A Look at WCLC 2026: Pivotal Trials and Emerging Directions
Project Oncology®
A Look at WCLC 2026: Pivotal Trials and Emerging Directions
Triparna Sen, PhD
- Triparna Sen, PhD
Closing Gaps in CRC Screening: From Stool-Based Testing to Timely Colonoscopy
Closing Gaps in CRC Screening: From Stool-Based Testing to Timely Colonoscopy
Clinician's Roundtable
Closing Gaps in CRC Screening: From Stool-Based Testing to Timely Colonoscopy
Shelina Ramnarine, PhD; David A. Johnson, MD, FACG, FACP
- Shelina Ramnarine, PhD
- David A. Johnson, MD, FACG, FACP
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
MinuteCE®
Redefining Endocrine Therapy: The Evidence Behind Oral SERDs and PROTAC ER Degraders
Komal Jhaveri, MD, FACP
0.50 program credits
- Komal Jhaveri, MD, FACP
0.50 program credits
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
MinuteCE®
Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
Komal Jhaveri, MD, FACP; Virginia Kaklamani, MD, DSc
0.50 program credits
- Komal Jhaveri, MD, FACP
- Virginia Kaklamani, MD, DSc
0.50 program credits